Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~487 deaths, have been reported worldwide. Notably, the recent human-to-human ‘superspreading’ of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.

[1]  Andy Kilianski,et al.  Assessing Activity and Inhibition of Middle East Respiratory Syndrome Coronavirus Papain-Like and 3C-Like Proteases Using Luciferase-Based Biosensors , 2013, Journal of Virology.

[2]  Arun K. Ghosh,et al.  Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro) , 2015, The Journal of Biological Chemistry.

[3]  M. Frieman,et al.  Emergence of the Middle East Respiratory Syndrome Coronavirus , 2013, PLoS pathogens.

[4]  Zhongbin Chen,et al.  Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. , 2014, The Journal of general virology.

[5]  F. Weber,et al.  Middle East Respiratory Syndrome Coronavirus Accessory Protein 4a Is a Type I Interferon Antagonist , 2013, Journal of Virology.

[6]  M. Müller,et al.  In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection , 2013, Virology Journal.

[7]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[8]  I. Mackay,et al.  Middle East respiratory syndrome: An emerging coronavirus infection tracked by the crowd , 2015, Virus Research.

[9]  J. Torres,et al.  MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels , 2015, Virus Research.

[10]  A. Mesecar,et al.  MERS-CoV papain-like protease has deISGylating and deubiquitinating activities , 2013, Virology.

[11]  Arun K. Ghosh,et al.  Inhibitor Recognition Specificity of MERS-CoV Papain-like Protease May Differ from That of SARS-CoV , 2015, ACS chemical biology.

[12]  G. Olinger,et al.  Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. , 2014, The Journal of general virology.

[13]  G. Sutter,et al.  Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein , 2015, Journal of Virology.

[14]  P. Woo,et al.  Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5 , 2012, Emerging Microbes & Infections.

[15]  Chao-Hsiung Lin,et al.  Structural and functional characterization of MERS coronavirus papain-like protease , 2014, Journal of Biomedical Science.

[16]  R. Baric,et al.  Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.

[17]  S. Perlman,et al.  Coronaviruses post-SARS: update on replication and pathogenesis , 2009, Nature Reviews Microbiology.

[18]  M. Müller,et al.  Replicative Capacity of MERS Coronavirus in Livestock Cell Lines , 2014, Emerging infectious diseases.

[19]  R. Fouchier,et al.  MERS: emergence of a novel human coronavirus , 2014, Current Opinion in Virology.

[20]  Linqi Zhang,et al.  Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 , 2013, Cell Research.

[21]  Sangdun Choi,et al.  Negative regulatory approaches to the attenuation of Toll-like receptor signaling , 2013, Experimental & Molecular Medicine.

[22]  B. Bosch,et al.  Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody , 2013, Journal of Virology.

[23]  Lu Lu,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein , 2014, Virus Research.

[24]  Christian Drosten,et al.  Targeting Membrane-Bound Viral RNA Synthesis Reveals Potent Inhibition of Diverse Coronaviruses Including the Middle East Respiratory Syndrome Virus , 2014, PLoS pathogens.

[25]  P. Roberts,et al.  Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. , 2000, Immunity.

[26]  A. Debnath,et al.  A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC , 2012, Journal of Infection.

[27]  Ralph S. Baric,et al.  A decade after SARS: strategies for controlling emerging coronaviruses , 2013, Nature Reviews Microbiology.

[28]  D. Levy,et al.  The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. , 2001, Cytokine & growth factor reviews.

[29]  Krystal L. Matthews,et al.  The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. , 2014, The Journal of general virology.

[30]  M. Buchmeier,et al.  Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines , 2012, mBio.

[31]  R. Couch,et al.  Generation of a Transgenic Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease , 2015, Journal of Virology.

[32]  P. Rottier,et al.  Live, Attenuated Coronavirus Vaccines through the Directed Deletion of Group-Specific Genes Provide Protection against Feline Infectious Peritonitis , 2004, Journal of Virology.

[33]  Z. Memish,et al.  Middle East respiratory syndrome coronavirus: transmission and phylogenetic evolution , 2014, Trends in Microbiology.

[34]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[35]  M. Yoneyama,et al.  Triggering antiviral response by RIG-I-related RNA helicases. , 2007, Biochimie.

[36]  G. Yancopoulos,et al.  Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection , 2015, Proceedings of the National Academy of Sciences.

[37]  Samson S. Y. Wong,et al.  Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia , 2005, Journal of Virology.

[38]  H. Rashid,et al.  Middle East Respiratory Syndrome Coronavirus “MERS-CoV”: Current Knowledge Gaps , 2015, Paediatric Respiratory Reviews.

[39]  T. Bestebroer,et al.  Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.

[40]  A. Billiau.  Interferon: the pathways of discovery I. Molecular and cellular aspects. , 2006, Cytokine & growth factor reviews.

[41]  Shibo Jiang,et al.  Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.

[42]  J. Chan,et al.  The emerging novel Middle East respiratory syndrome coronavirus: The “knowns” and “unknowns” , 2013, Journal of the Formosan Medical Association.

[43]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[44]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[45]  P. Formenty,et al.  State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans , 2013, PLoS currents.

[46]  S. Cusack,et al.  Structural Basis for the Activation of Innate Immune Pattern-Recognition Receptor RIG-I by Viral RNA , 2011, Cell.

[47]  A. Mesecar,et al.  Catalytic Function and Substrate Specificity of the Papain-Like Protease Domain of nsp3 from the Middle East Respiratory Syndrome Coronavirus , 2014, Journal of Virology.

[48]  T. Fujita,et al.  RIG‐I‐like receptors: cytoplasmic sensors for non‐self RNA , 2011, Immunological reviews.

[49]  Lu Lu,et al.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.

[50]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[51]  Christian Drosten,et al.  Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. , 2013, American journal of respiratory and critical care medicine.

[52]  D. Swerdlow,et al.  Unraveling the Mysteries of Middle East Respiratory Syndrome Coronavirus , 2014, Emerging infectious diseases.

[53]  Malik Peiris,et al.  Middle East respiratory syndrome , 2015, The Lancet.

[54]  S. Morikawa,et al.  Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Brian L. Mark,et al.  Crystal Structure of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Papain-like Protease Bound to Ubiquitin Facilitates Targeted Disruption of Deubiquitinating Activity to Demonstrate Its Role in Innate Immune Suppression , 2014, The Journal of Biological Chemistry.

[56]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[57]  D. Swerdlow,et al.  Middle East Respiratory Syndrome Coronavirus: Update for Clinicians , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  P. Rottier,et al.  The Group-Specific Murine Coronavirus Genes Are Not Essential, but Their Deletion, by Reverse Genetics, Is Attenuating in the Natural Host , 2002, Virology.

[59]  B. Bosch,et al.  Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[60]  J. Kahn,et al.  History and Recent Advances in Coronavirus Discovery , 2005, The Pediatric infectious disease journal.

[61]  K. To,et al.  Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.

[62]  K. Yuen,et al.  Middle East Respiratory Syndrome Coronavirus 4a Protein Is a Double-Stranded RNA-Binding Protein That Suppresses PACT-Induced Activation of RIG-I and MDA5 in the Innate Antiviral Response , 2014, Journal of Virology.

[63]  Stuart G. Siddell,et al.  A Contemporary View of Coronavirus Transcription , 2006, Journal of Virology.

[64]  Z. Memish,et al.  What are our pharmacotherapeutic options for MERS-CoV? , 2014, Expert review of clinical pharmacology.

[65]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[66]  M. Vignuzzi,et al.  Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics , 2013, PLoS pathogens.

[67]  K. To,et al.  Differential Cell Line Susceptibility to the Emerging Novel Human Betacoronavirus 2c EMC/2012: Implications for Disease Pathogenesis and Clinical Manifestation , 2013, The Journal of infectious diseases.

[68]  Yang Yang,et al.  The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists , 2013, Protein & Cell.

[69]  S. Locarnini,et al.  Toll‐like receptors, RIG‐I‐like RNA helicases and the antiviral innate immune response , 2007, Immunology and cell biology.

[70]  B. Bosch,et al.  Spiking the MERS-coronavirus receptor , 2013, Cell Research.

[71]  D. Waugh,et al.  Structures of the Middle East respiratory syndrome coronavirus 3C‐like protease reveal insights into substrate specificity , 2015, Acta crystallographica. Section D, Biological crystallography.

[72]  P. Rottier,et al.  Molecular Interactions in the Assembly of Coronaviruses , 2005, Advances in Virus Research.

[73]  M. Peiris,et al.  A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus , 2015, The Lancet Infectious Diseases.

[74]  T. Bestebroer,et al.  MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment , 2013, The Journal of general virology.

[75]  Sangdun Choi,et al.  Toll-like receptor signal transduction , 2007, Experimental & Molecular Medicine.

[76]  Rolf Hilgenfeld,et al.  Accessory proteins of SARS-CoV and other coronaviruses , 2014, Antiviral Research.

[77]  S. Sarafianos,et al.  Evaluation of SSYA10-001 as a Replication Inhibitor of Severe Acute Respiratory Syndrome, Mouse Hepatitis, and Middle East Respiratory Syndrome Coronaviruses , 2014, Antimicrobial Agents and Chemotherapy.

[78]  S. Weiss,et al.  Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus , 2005, Microbiology and Molecular Biology Reviews.